Editorial

CROATIAN CONSENSUS ON THE TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH BIOLOGIC THERAPY

BORIS VUCELIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
SILVIJA ČUKOVIĆ-ČAVKA ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MARKO BANIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
ANTE BILIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
VLADIMIR BORZAN ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MARKO DUVNJAK ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MIROSLAVA KATIČIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
SANJA KOLAČEK ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
ŽELJKO KRZNARIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MILAN KUJUNDŽIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MARINKO MARUŠIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
SILVIO MIHALJEVIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
BRANKICA SINČIĆ MIJANDRUŠIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MLADEN PERŠIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
MIROSLAV ŠIMUNIĆ ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia
BRUNO ŠKURLA ; Referral Center of the Ministry of Health of the Republic of Croatia for Chronic Inflammatory Bowel Diseases, IBD Section, Croatian Society of Gastroenterology, Zagreb, Croatia

Abstract

Introduction of biologic therapy in clinical practice represented significant progress in the treatment of inflammatory bowel diseases
(IBD) because of its proven efficacy and due to the fact that biologics are the first drugs used in the treatment of IBD that
can change the natural course of this diseases. At the same time, biologics are very expensive drugs with complex mechanism
of action and important side effects and their use requires evidence-based clinical guidelines. These were the reasons that Referral
Center of the Croatian Ministry of Health for IBD and the IBD Section of the Croatian Society of Gastroenterology organised
Croatian consensus conference that defined guidelines for the treatment of IBD with anti-TNF drugs. The text below includes
definitions of IBD, general principles of IBD therapy, comments on the importance of mucosal healing, analysis of reasons for
nonresponse and loss of response to anti-TNF drugs, recommendation for the duration of anti-TNF therapy, rules of screening for
opportunistic infections prior to anti-TNF therapy, comments on the problems with reproduction in IBD and finally guidelines for
the treatment of various phenotypes of IBD including extraintestinal manifestations with anti-TNF therapy.

Keywords

inflammatory bowel diseases; ulcerative colitis; Crohn’s disease; biologic therapy; Croatian consensus

Hrčak ID:

111250

URI

https://hrcak.srce.hr/111250

Publication date:

28.11.2013.

Article data in other languages: croatian

Visits: 6.612 *